- ICH GCP
- EU Clinical Trials Registry
Latest Trials
EudraCT Number: 2018-003323-10 | Sponsor Protocol Number: V712-305(EPOPEX) | Start Date: | |||||||||||
Sponsor Name: DBV TECHNOLOGIES S.A. | |||||||||||||
Full Title: EPITOPE OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM CLINICAL BENEFIT AND SAFETY OF DBV712 IN PEANUT-ALLERGIC CHILDREN (EPOPEX) | |||||||||||||
Medical condition: Peanut allergy | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Ongoing) GB (GB - no longer in EU/EEA) NL (Ongoing) DE (Ongoing) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004734-11 | Sponsor Protocol Number: J1S-MC-JP04 | Start Date: | |||||||||||
Sponsor Name: Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination with Irinotecan and Temozolomide in Participants with Relapsed or Refractory Ewing's Sarcoma | |||||||||||||
Medical condition: Ewing's Sarcoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) IT (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015988-13 | Sponsor Protocol Number: REC15/2375-IT-CL0336 | Start Date: | |||||||||||
Sponsor Name: Recordati S.p.A., | |||||||||||||
Full Title: An international multicentre, randomized, parallel group, double-blind trial to evaluate different dose combinations of lercanidipine and enalapril in comparison with each component administered al... | |||||||||||||
Medical condition: Essential hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) FR (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003314-24 | Sponsor Protocol Number: CC-10004-PPSO-001 | Start Date: | ||||||||||||||||
Sponsor Name: Celgene Corporation | ||||||||||||||||||
Full Title: A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects with Moderate to Severe Plaque Psoriasis | ||||||||||||||||||
Medical condition: Moderate to severe plaque psoriasis in adolescents (ages 12 to 17 years, inclusive) and in children (ages 6 to 11 years, inclusive). | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) DE (Completed) ES (Completed) Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-001491-21 | Sponsor Protocol Number: 1-2006 | Start Date: | ||||||
Sponsor Name: Max Planck Institute of Psychiatry | ||||||||
Full Title: Studies on Permeability of the Blood-Brain-Barrier for Escitaloprame related to various Genotypes of the ABCB1-Gene: Effects on Sleep and Motoric Learning | ||||||||
Medical condition: Effects on sleep electroencephalogram and motoric learning in healthy volunteers related to the permeability of the blood-brain-barrier related to genotypes of the ABCB 1 gene | ||||||||
|
||||||||
Population Age: Adults | Gender: Male | |||||||
Trial protocol: DE (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004167-27 | Sponsor Protocol Number: RM-493-033 | Start Date: | |||||||||||||||||||||
Sponsor Name: Rhythm Pharmaceuticals Limited | |||||||||||||||||||||||
Full Title: A Phase 3 Multi-Center, One-Year, Open-Label study of Setmelanotide in Pediatric Patients Aged 2 to | |||||||||||||||||||||||
Medical condition: POMC deficiency obesity due to mutations in the POMC gene PCSK1 deficiency due to mutations in the PCSK1 gene LEPR deficiency obesity due to mutations in the LEPR gene Bardet-Biedl syndrome | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001571-21 | Sponsor Protocol Number: P18.037 | Start Date: | ||||||
Sponsor Name: Leiden University | ||||||||
Full Title: Training immune functions through pharmacotherapeutic conditioning in juvenile idiopathic arthritis | ||||||||
Medical condition: Juvenile Idiopathic Arthritis | ||||||||
|
||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||
Trial protocol: NL (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002858-24 | Sponsor Protocol Number: D-CA-60130-452 | Start Date: | |||||||||||
Sponsor Name: Clementia Pharmaceuticals Inc, an Ipsen Company | |||||||||||||
Full Title: A Phase 2, two-part, placebo-controlled, parallel-group, double-blind study to assess the efficacy and safety of 2 dosage regimens of oral IPN60130 for the treatment of fibrodysplasia ossificans pr... | |||||||||||||
Medical condition: fibrodysplasia ossificans progressiva (FOP) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) SE (Ongoing) IT (Ongoing) ES (Ongoing) NL (Ongoing) BE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005429-21 | Sponsor Protocol Number: OPTIMIST-Aprotocol | Start Date: | |||||||||||
Sponsor Name: Menzies Research Institute Tasmania | |||||||||||||
Full Title: Multicentre randomised controlled trial of minimally-invasive surfactant therapy in preterm infants 25-28 weeks gestation on continuous positive airway pressure (CPAP) | |||||||||||||
Medical condition: Infant respiratory distress syndrome, also known as hyaline membrane disease. | |||||||||||||
|
|||||||||||||
Population Age: In utero, Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) Outside EU/EEA SI (Ongoing) NL () | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-008689-11 | Sponsor Protocol Number: 3/15.12.2008 | Start Date: | ||||||
Sponsor Name: Children's Memorial Health Institute | ||||||||
Full Title: Efficacy and safety of omega – 3 based lipid solution (Omegaven) in comparison with Lipofundin LCT/MCT in reducing cholestasis in children on parenteral nutrition – randomized double – blind clinic... | ||||||||
Medical condition: Parenteral nutrition associated liver disease (PNALD) MedDRA LLT: total parenteral nutrition MedDRA PT: parenteral nutrition MedDRA LLT: liver cholestasis MedDRA PT: cholestasis | ||||||||
|
||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||
Trial protocol: PL (Prematurely Ended) | ||||||||
Trial results: (No results available) |